Press Releases Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news. IR Sub Menu Investors & Media Corporate Profile Press Releases Events & Presentations Publications Year None202320222021202020192018201720162015 Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting 12/13/2021 Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021 11/09/2021 Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting 11/09/2021 Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences 11/03/2021 Poseida Therapeutics Announces Leadership Appointments 10/13/2021 Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies 10/12/2021 Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting 10/01/2021 Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences 09/07/2021 Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit 08/31/2021 Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma 08/30/2021 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 31 - 40 of 112
Year None202320222021202020192018201720162015 Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting 12/13/2021 Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021 11/09/2021 Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting 11/09/2021 Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences 11/03/2021 Poseida Therapeutics Announces Leadership Appointments 10/13/2021 Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies 10/12/2021 Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting 10/01/2021 Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences 09/07/2021 Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit 08/31/2021 Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma 08/30/2021 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 31 - 40 of 112
Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting 12/13/2021
Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021 11/09/2021
Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting 11/09/2021
Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies 10/12/2021
Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting 10/01/2021
Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit 08/31/2021
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma 08/30/2021